The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis.

Q2 Medicine

The Journal of rheumatology. Supplement Pub Date : 2022-09-01 Epub Date: 2022-04-01 DOI:10.3899/jrheum.211316

Stephanie J W Shoop-Worrall, Louisa Moull, Janet E McDonagh, Kimme L Hyrich

引用次数: 0

Abstract

Objective: To investigate the relationship between age and symptom duration at initial presentation to pediatric rheumatology for juvenile idiopathic arthritis (JIA).

Methods: In children and young people (CYP) enrolled in the Childhood Arthritis Prospective Study prior to March 2018, an association between age at presentation (< 5, 5-11, and > 11 yrs) and symptom duration was tested by multivariable linear regression.

Results: In 1577 CYP, 5- to 11-year-olds took 3.2 months longer and > 11-year-olds 6.9 months longer to reach pediatric rheumatology than < 5-year-olds.

Conclusion: Adolescents take longer to reach pediatric rheumatology, potentially affecting their longer-term outcomes given the window of opportunity for JIA treatment.

查看原文本刊更多论文

年龄在青少年特发性关节炎风湿病治疗延迟中的作用。

目的：研究幼年特发性关节炎（JIA）初次就诊时年龄与症状持续时间之间的关系：研究幼年特发性关节炎（JIA）初次就诊时的年龄与症状持续时间之间的关系：在2018年3月之前加入儿童关节炎前瞻性研究（Childhood Arthritis Prospective Study）的儿童和青少年（CYP）中，通过多变量线性回归检验了就诊年龄（< 5岁、5-11岁和> 11岁）与症状持续时间之间的关系：在1577例CYP中，与5岁儿童相比，5至11岁儿童就诊儿科风湿病的时间长3.2个月，11岁儿童则长6.9个月：青少年到儿科风湿免疫科就诊的时间更长，这可能会影响他们的长期治疗效果，因为JIA的治疗时机尚不成熟。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of rheumatology. Supplement Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.